A Randomized, Placebo-Controlled Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Lu AG06466 (Primary)
- Indications Gilles de la Tourette's syndrome; Tic disorders
- Focus Therapeutic Use
- Sponsors Abide Therapeutics; Lundbeck A/S
- 19 Nov 2019 Planned End Date changed from 1 Nov 2019 to 1 Feb 2020.
- 19 Nov 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Feb 2020.
- 19 Nov 2019 Status changed from recruiting to active, no longer recruiting.